Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 174

Sort by

Sort Order Select

Journal Articles

Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial

Blood blood.2025029210.

https://doi.org/10.1182/blood.2025029210

Published: 2025

Includes: Supplemental data

Journal Articles

Modification of post-trogocytosis effects to Enhance CAR-t cell persistence

Jianxiang Wang, Haotian Ma, Heye Yu, Shangshang Wang, Fan Ding, Haoren Wang, Wei Li, Yingxi Xu, Shaowei Qiu, Haiyan Xing, Kejing Tang, Zheng Tian, Qing Rao, Runxia Gu, Min Wang

Blood (2025) 146 (Supplement 1): 810.

https://doi.org/10.1182/blood-2025-810

Published: 2025

Journal Articles

Engineering Quiescent Viral Entry Pathways for in Vivo CAR-T Generation via Binder-Fusogen Combinatorics

xiaoling wang, wancheng yang, kaiyuan wang, Jiapan Hu, yixuan zhou, Ying Wang, yingyong xu, Jianxiang Wang, Jeremy Luban, Luhan Yang

Blood (2025) 146 (Supplement 1): 2404.

https://doi.org/10.1182/blood-2025-2404

Published: 2025

Journal Articles

Effect of the dominant-negative ikaros isoform 6 (Ik6) on cell function and drug sensitivity in acute lymphoblastic leukemia cell lines

Qishan Hao, Juan Feng, Meizhen Xu, Yanan Jia, Qiuyun Fang, Yan Li, Zheng Tian, Min Wang, Jianxiang Wang, Yingchang Mi

Blood (2025) 146 (Supplement 1): 6827.

https://doi.org/10.1182/blood-2025-6827

Published: 2025

Journal Articles

Synergistic integration of CAR-T cell pharmacokinetics and NGS-MRD evolution enables precision risk stratification in relapsed/refractory B-cell acute lymphoblastic leukemia

Runxia Gu, Shuning Wei, Shaowei Qiu, Xiaoyuan Gong, Guangji Zhang, Benfa Gong, Qiuyun Fang, Shouyun Li, Kaiqi Liu, Dong Lin, Ying Wang, Chunlin Zhou, Bingcheng LIU, Yingchang Mi, Hui Wei, Jianxiang Wang, Ying Wang

Blood (2025) 146 (Supplement 1): 3366.

https://doi.org/10.1182/blood-2025-3366

Published: 2025

Journal Articles

Distinct patterns of mutant ASXL1 over time and their implications for treatment failure (TF) and BCR::ABL1 mutation development in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS-TKI) in the ASC4FIRST study

Blood (2025) 146 (Supplement 1): 73.

https://doi.org/10.1182/blood-2025-73

Published: 2025

Journal Articles

1,200+ U2AF1 mutations reveal distinct clinicobiological features of the S34/Q157 co-mutation subgroup

Yujiao Jia, Haoxu Wang, Bingqing Huang, Li Qin, Jiao Chang, Ruixue Zhang, Jinqin Liu, Hui Wei, Jianxiang Wang, Jun Shi, Qi Sun, Zhijian Xiao

Blood (2025) 146 (Supplement 1): 3499.

https://doi.org/10.1182/blood-2025-3499

Published: 2025

Journal Articles

Front-line consolidation with CAR-t therapy in newly diagnosed adult ph-negative b-acute lymphoblastic leukemia: Results from a prospective, phase 2 study

Runxia Gu, Shaowei Qiu, Wenbing Liu, Xiaoyuan Gong, Shuning Wei, Guangji Zhang, Benfa Gong, Qiuyun Fang, Shouyun Li, Kaiqi Liu, Dong Lin, Ying Wang, Chunlin Zhou, Chengcai Guo, Bingcheng LIU, Yingchang Mi, Hui Wei, Ying Wang, Jianxiang Wang

Blood (2025) 146 (Supplement 1): 1561.

https://doi.org/10.1182/blood-2025-1561

Published: 2025

Journal Articles

Designing immune-evasive ucar-T cells to overcome allogeneic barriers and advance off-the-shelf immunotherapy

jiabiao hu, Yanan Yue, tianying chen, lina zhou, xiaomeng Bian, xiaobin song, huan chen, xu feng, yuqing lin, yixuan zhou, yingyong xu, Jianxiang Wang, Ying Wang, george church, Luhan Yang

Blood (2025) 146 (Supplement 1): 1045.

https://doi.org/10.1182/blood-2025-1045

Published: 2025

Journal Articles

This is a title in sentence case: Venetoclax-based regimens versus intensive chemotherapy in fit older adults with newly diagnosed acute myeloid leukemia (AML)：a multicenter, prospective, randomized phase II trial

Qiuyun Fang, Fei Li, Aijun Liao, Qingsong Yin, Lin Yang, Lianrong Xu, Junjie Ma, Junqing Xu, Hao Zhang, Jieyu Wang, Shaowei Qiu, Bingcheng LIU, Yingchang Mi, Jianxiang Wang, Hui Wei

Blood (2025) 146 (Supplement 1): 650.

https://doi.org/10.1182/blood-2025-650

Published: 2025

Journal Articles

Updated results from the Phase 1b/2 study of MK-1045, a novel CD19xCD3 T-cell engager, in adult participants with relapsed or refractory B-cell acute lymphoblastic leukemia

Ying Wang, Qingsong Yin, Jinhai Ren, Hongsheng Zhou, Tiejun Gong, Feng Zhu, Xi Zhang, Qin Wen, Heng Mei, Wei Huang, Zhenghong Chen, Bhargava Kandala, Jingxia Chen, Jianxiang Wang

Blood (2025) 146 (Supplement 1): 647.

https://doi.org/10.1182/blood-2025-647

Published: 2025

Journal Articles

Oral–Gut microbiome coalescence and ecosystem fragility promote drug-resistant colonization and infection in relapsed/refractory leukemia

xiaomeng feng, Erlie Jiang, Jianxiang Wang, Sizhou Feng

Blood (2025) 146 (Supplement 1): 5267.

https://doi.org/10.1182/blood-2025-5267

Published: 2025

Journal Articles

Inhibition of CPT1A reverses AML1-ETO-induced differentiation blockage by activating BCL-2/MYC signaling and metabolic reprogramming

Shaowei Qiu, Fan Ding, Yu Liu, Haoren Wang, Qing Rao, Runxia Gu, Min Wang, Jianxiang Wang

Blood (2025) 146 (Supplement 1): 3224.

https://doi.org/10.1182/blood-2025-3224

Published: 2025

Journal Articles

CYP3A4 inhibitors (CYP3A4i) and myelosuppression in patients (Pts) with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) in the phase 3 AGILE study

Andre Schuh, Pau Montesinos, Christian Recher, Michael Heuser, Susana Vives, Ewa Zarzycka, Marta Riva, Rodrigo Calado, Su-Peng Yeh, Courtney DiNardo, Mohammad Hossain, Jianan Hui, Diego Gianolio, Assaf Vestin, Rui Ding, Prapti Patel, Stéphane De Botton, Hartmut Döhner, Jianxiang Wang

Blood (2025) 146 (Supplement 1): 3440.

https://doi.org/10.1182/blood-2025-3440

Published: 2025

Journal Articles

Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis

Blood (2025) 146 (Supplement 1): 1997.

https://doi.org/10.1182/blood-2025-1997

Published: 2025

Journal Articles

Research on co-mutated genes in FLT3-ITD-positive acute myeloid leukemia

Li Wan, Yujiao Jia, Yan Li, Jiao Ma, Haiwei Li, Yao Yao, Hui Wei, Jianxiang Wang, Zhijian Xiao, Yingchang Mi

Blood (2025) 146 (Supplement 1): 7027.

https://doi.org/10.1182/blood-2025-7027

Published: 2025

Journal Articles

Rapid normalization of platelet counts in patients with refractory thrombocytopenia associated with systemic lupus erythematosus (SLE) following treatment with allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B)

Blood (2025) 146 (Supplement 1): 3031.

https://doi.org/10.1182/blood-2025-3031

Published: 2025

Journal Articles

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with Philadelphia chromosome-positive b-ALL: Insights from real-world data

Blood (2025) 146 (Supplement 1): 6855.

https://doi.org/10.1182/blood-2025-6855

Published: 2025

Journal Articles

Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial

Blood (2025) 146 (Supplement 1): 5549.

https://doi.org/10.1182/blood-2025-5549

Published: 2025

Journal Articles

Bleximenib or placebo in combination with standard induction and consolidation therapy followed by maintenance for the treatment of patients with newly diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia eligible for intensive chemotherapy: A double-blind Phase 3 study (HOVON 181 AML / AMLSG 37-25)

Blood (2025) 146 (Supplement 1): 1654.

https://doi.org/10.1182/blood-2025-1654

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial

Modification of post-trogocytosis effects to Enhance CAR-t cell persistence

Engineering Quiescent Viral Entry Pathways for in Vivo CAR-T Generation via Binder-Fusogen Combinatorics

Effect of the dominant-negative ikaros isoform 6 (Ik6) on cell function and drug sensitivity in acute lymphoblastic leukemia cell lines

Synergistic integration of CAR-T cell pharmacokinetics and NGS-MRD evolution enables precision risk stratification in relapsed/refractory B-cell acute lymphoblastic leukemia

1,200+ U2AF1 mutations reveal distinct clinicobiological features of the S34/Q157 co-mutation subgroup

Front-line consolidation with CAR-t therapy in newly diagnosed adult ph-negative b-acute lymphoblastic leukemia: Results from a prospective, phase 2 study

Designing immune-evasive ucar-T cells to overcome allogeneic barriers and advance off-the-shelf immunotherapy

This is a title in sentence case: Venetoclax-based regimens versus intensive chemotherapy in fit older adults with newly diagnosed acute myeloid leukemia (AML)：a multicenter, prospective, randomized phase II trial

Updated results from the Phase 1b/2 study of MK-1045, a novel CD19xCD3 T-cell engager, in adult participants with relapsed or refractory B-cell acute lymphoblastic leukemia

Oral–Gut microbiome coalescence and ecosystem fragility promote drug-resistant colonization and infection in relapsed/refractory leukemia

Inhibition of CPT1A reverses AML1-ETO-induced differentiation blockage by activating BCL-2/MYC signaling and metabolic reprogramming

CYP3A4 inhibitors (CYP3A4i) and myelosuppression in patients (Pts) with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) in the phase 3 AGILE study

Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis

Research on co-mutated genes in FLT3-ITD-positive acute myeloid leukemia

Rapid normalization of platelet counts in patients with refractory thrombocytopenia associated with systemic lupus erythematosus (SLE) following treatment with allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B)

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with Philadelphia chromosome-positive b-ALL: Insights from real-world data

Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only